secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001576280-24-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q4 rev $155.1M (+22% YoY); GAAP net loss $187.0M incl $83.4M legal accrual; 2024 guidance $655-670M
--------------------------------------------------------------------------------

- Fourth quarter 2023 revenue $155.1M, up 22% YoY; full year revenue $563.9M, up 25%.
- GAAP net loss Q4 $187.0M ($1.58 per share) vs $139.9M ($1.36) prior year, including $83.4M non-recurring legal accrual.
- Clinical test volume 46,400 in Q4 (+29% YoY); full year 172,900 (+39% YoY).
- 2024 revenue guidance $655-670M (16-19% growth); non-GAAP op expense $740-750M; free cash flow -$320 to -$330M.
- Cash and marketable securities $1.2B at year-end; Shield PMA submission under FDA review, expect FDA approval and launch in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/gh-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001576280-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer